Update on the treatment of neuroendocrine tumors

Emilio Bajetta(Fondazione Lanza), Emilio Bombardieri(Humanitas Gavazzeni), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Laura Catena(Fondazione IRCCS Istituto Nazionale dei Tumori), Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Leonardo Ferrari(Fondazione IRCCS Istituto Nazionale dei Tumori)
Expert Review of Anticancer Therapy
October 1, 2003
10.1586/14737140.3.5.631
Cited by 27

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780